Blockbuster PD-L1 inhibitor is approved by FDA to treat early lung cancer and reduce the risk of recurrence by 34%

On October 16, Roche announced that the US FDA has approved its blockbuster PD-L1 inhibitor Tecentriq (atezolizumab) as an adjuvant therapy to treat stage II-IIIA non-small cell lung cancer (NSCLC) after surgery and platinum-containing chemotherapy.

This approval is based on the results of an interim analysis of a phase 3 clinical trial

▲The efficacy of Tecentriq in stage II-IIIA NSCLC patients whose tumors express PD-L1 (picture source: reference [2])

In terms of safety, Tecentriq's safety characteristics are consistent with known characteristics, and no new safety signals have been found

Non-small cell lung cancer accounts for about 80-85% of all lung cancers, and about half of early-stage patients will still experience cancer recurrence after surgery

(The original text has been deleted)

Reference materials:

[1] US FDA approves Roche's Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer.

[2] Roche Analyst Event Tuesday, 08 June 2021.